Purple Biotech Forms Scientific Advisory Board
Ticker: PPBT · Form: 6-K · Filed: Apr 23, 2026 · CIK: 0001614744
Sentiment: neutral
Topics: biotech, R&D, advisory-board
TL;DR
Purple Biotech just formed a SAB to speed up their C-series drug development. Big news for R&D!
AI Summary
Purple Biotech Ltd. announced on April 23, 2026, the establishment of a Scientific Advisory Board (SAB) to bolster the development of its C-series drug candidates. The SAB will comprise leading experts in the field, aiming to accelerate the company's research and development efforts.
Why It Matters
The formation of a Scientific Advisory Board indicates a strategic move to enhance drug development capabilities, potentially speeding up the timeline for bringing new therapies to market.
Risk Assessment
Risk Level: low — This filing is an announcement of a board formation, which is a standard corporate action with no immediate financial implications or significant new risks disclosed.
Key Players & Entities
- Purple Biotech Ltd. (company) — Filer of the report and company forming the SAB
- C-series drug candidates (drug_candidate) — Area of focus for the Scientific Advisory Board
FAQ
When was this report filed?
The report was filed on April 23, 2026.
What is the primary purpose of the Scientific Advisory Board?
The Scientific Advisory Board is established to support the development of Purple Biotech's C-series drug candidates.
What type of company is Purple Biotech Ltd.?
Purple Biotech Ltd. is a foreign private issuer, classified under SIC code 2834 for Pharmaceutical Preparations.
What is the CIK number for Purple Biotech Ltd.?
The CIK number for Purple Biotech Ltd. is 0001614744.
Where is Purple Biotech Ltd. located?
Purple Biotech Ltd.'s business and mailing address is 4 Oppenheimer Street, Science Park, Rehovot, L3 7670104.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 23, 2026 regarding PURPLE BIOTECH LTD. (PPBT).